Employers need to have a wider horizon than drug costs alone when considering the implementation of health care intervention programs.
Wahlqvist
Peter
P
D002170:Canada; D016527:Drug Costs; D017723:Drug Utilization Review; D004415:Dyspepsia / Q000188:drug therapy; D017049:Employer Health Costs; D004791:Enzyme Inhibitors / Q000191:economics; D005764:Gastroesophageal Reflux / Q000188:drug therapy / Q000191:economics; D006264:Health Benefit Plans, Employee / Q000592:standards*; D006801:Humans; D007356:Insurance, Pharmaceutical Services / Q000592:standards; D008329:Managed Care Programs / Q000191:economics / Q000592:standards*; D011306:Prescription Fees; D054328:Proton Pump Inhibitors; D011787:Quality of Health Care; D013810:Therapeutic Equivalency
D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors